Investigations into Amedisys Inc.'s therapy provision by The Wall Street Journal, U.S. Senate, Securities and Exchange Commission, Department of Justice, and others seem to be taking their toll. The Baton Rouge, La.-based national chain reported a 40 percent drop in profits for the quarter ended Sept. 30, compared to the year-ago quarter. Amedisys reported net income of $21.8 million for the quarter, down from $35.9 million in 2009. Net revenue grew 4 percent in the period, from $388.3 million to $404.7 million. "The quarter's results reflect the volume fall-off we began experiencing in the second quarter," CEO William Borne says in a release. "We have implemented a number of initiatives to better align our cost structure with current volume and improve our revenue moving forward."